Immunocore gains as Mizuho maintains buy rating
| IMCR Stock | USD 30.46 0.31 1.03% |
Slightly above 50% of Immunocore Holdings' retail investors are presently thinking to get in. The analysis of overall sentiment of trading Immunocore Holdings stock suggests that some investors are interested at this time. Immunocore Holdings' investing sentiment overview a quick insight into current market opportunities from investing in Immunocore Holdings. Many technical investors use Immunocore Holdings stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Immunocore | Build AI portfolio with Immunocore Stock |
Immunocore gains as Mizuho maintains buy rating
Read at investing.com
 |
Immunocore Holdings Fundamental Analysis
We analyze Immunocore Holdings' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunocore Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunocore Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
Immunocore Holdings is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Immunocore Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immunocore Holdings stock to make a market-neutral strategy. Peer analysis of Immunocore Holdings could also be used in its relative valuation, which is a method of valuing Immunocore Holdings by comparing valuation metrics with similar companies.
Peers
Immunocore Holdings Related Equities
| ERAS | Erasca | 6.04 | ||||
| VTYX | Ventyx Biosciences | 5.07 | ||||
| LRMR | Larimar Therapeutics | 3.85 | ||||
| NUVL | Nuvalent | 1.61 | ||||
| GLUE | Monte Rosa | 1.43 | ||||
| MIRM | Mirum Pharmaceuticals | 0.62 | ||||
| PCVX | Vaxcyte | 0.43 | ||||
| ACLX | Arcellx | 0.03 | ||||
| KALV | Kalvista Pharmaceuticals | 0.37 | ||||
| VRDN | Viridian Therapeutics | 0.87 | ||||
| DSGN | Design Therapeutics | 1.27 | ||||
| LYRA | Lyra Therapeutics | 8.33 |
Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.